Bioventus (NYSE:BVS) Hits New 12-Month High – Should You Buy?

Bioventus Inc. (NYSE:BVS)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $13.65 and last traded at $13.58, with a volume of 77630 shares. The stock had previously closed at $13.31.

Analyst Ratings Changes

BVS has been the subject of several recent analyst reports. Craig Hallum upped their target price on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, September 27th. Canaccord Genuity Group lifted their price target on shares of Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th.

Bioventus Stock Up 0.1 %

The company has a debt-to-equity ratio of 1.82, a current ratio of 1.33 and a quick ratio of 0.96. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of 35.74 and a beta of 0.90. The firm has a 50-day moving average price of $11.51 and a two-hundred day moving average price of $8.09.

Bioventus (NYSE:BVS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.12. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. The company had revenue of $151.22 million for the quarter, compared to the consensus estimate of $137.70 million. During the same period last year, the company earned $0.14 earnings per share. As a group, sell-side analysts anticipate that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Insider Activity

In related news, Director John A. Bartholdson bought 25,500 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were acquired at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the acquisition, the director now owns 6,939,357 shares of the company’s stock, valued at approximately $59,331,502.35. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, Director John A. Bartholdson bought 80,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average cost of $8.55 per share, with a total value of $684,000.00. Following the completion of the purchase, the director now owns 6,913,857 shares of the company’s stock, valued at $59,113,477.35. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John A. Bartholdson bought 25,500 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were purchased at an average price of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the acquisition, the director now owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. 32.90% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in Bioventus by 401.5% in the second quarter. Renaissance Technologies LLC now owns 503,175 shares of the company’s stock valued at $2,893,000 after buying an additional 402,841 shares during the period. Marshall Wace LLP raised its stake in Bioventus by 38.2% in the 2nd quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock valued at $1,911,000 after acquiring an additional 91,843 shares during the period. LSV Asset Management acquired a new stake in Bioventus during the 1st quarter valued at $1,170,000. American Century Companies Inc. increased its holdings in shares of Bioventus by 289.5% in the second quarter. American Century Companies Inc. now owns 169,161 shares of the company’s stock valued at $973,000 after purchasing an additional 125,736 shares during the last quarter. Finally, Panagora Asset Management Inc. acquired a new position in shares of Bioventus in the second quarter valued at $787,000. Institutional investors own 62.94% of the company’s stock.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.